Seismic Therapeutic vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 36)
Seismic Therapeutic logo

Seismic Therapeutic

EmergingLife Sciences & BioTech

AI-Driven Immunology Drug Discovery

Seismic Therapeutic raised $222M+ total ($121M Series B in 2023, $25M in 2025) using its IMPACT ML platform; dosed first patient in Phase 1 for S-4321 bifunctional antibody in autoimmune disease.

AI VisibilityBeta
Overall Score
D36
Category Rank
#100 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
32
Gemini
33

About

Seismic Therapeutic is a clinical-stage biotechnology company based in Boston, Massachusetts that applies machine learning to the discovery and development of novel immunotherapies for autoimmune diseases. Founded with a focus on precision immunology, Seismic built its IMPACT platform to model the complex biology of adaptive immunity — identifying which immune cell populations drive specific autoimmune conditions and designing biologics that precisely modulate those populations without broadly suppressing the immune system. This targeted approach aims to produce safer, more effective treatments for conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#100
Category Rank
#10
76
AI Consensus
73
stable
Trend
stable
39
ChatGPT
72
32
Perplexity
68
33
Gemini
80
40
Claude
71
32
Grok
71

Key Details

Category
AI-Driven Immunology Drug Discovery
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.